Tadalafil

Three Months Ended March 31, Dollar Change Percentage Change 2025 2024 Total revenues $ 794.4 $ 677.7 $ 116.7 17 % Net income $ 322.2 $ 306.6 $ 15.6 5 % Net income, per basic share $ 7.18 $ 6.52 $ 0.66 10 % Net income, per diluted share $ 6.63 $ 6.17 $ 0.46 7 % Three Months Ended March 31, Dollar Change Percentage Change 2025 2024 Net product sales: Tyvaso DPI®(1) $ 302.5 $ 227.5 $ 75.0 33 % Nebulized Tyvaso®(1) 163.8 145.0 18.8 13 % Total Tyvaso 466.3 372.5 93.8 25 % Remodulin®(2) 138.2 128.0 10.2 8 % Orenitram® 120.7 106.2 14.5 14 % Unituxin® 58.2 58.4 (0.2 ) — % Adcirca® 6.0 6.4 (0.4 ) (6 )% Other 5.0 6.2 (1.2 ) (19 )% Total revenues $ 794.4 $ 677.7 $ 116.7 17 % (1) Net product sales include both the drug product and the respective inhalation device. (2) Net product sales include sales of infusion devices, including the Remunity® Pump. Three Months Ended March 31, 2025 2024 U.S. ROW Total U.S. ROW Total Net product sales: Tyvaso DPI(1) $ 302.5 $ — $ 302.5 $ 227.5 $ — $ 227.5 Nebulized Tyvaso(1) 138.6 25.2 163.8 133.7 11.3 145.0 Total Tyvaso 441.1 25.2 466.3 361.2 11.3 372.5 Remodulin(2) 120.2 18.0 138.2 108.3 19.7 128.0 Orenitram 120.7 — 120.7 106.2 — 106.2 Unituxin 56.9 1.3 58.2 53.4 5.0 58.4 Adcirca 6.0 — 6.0 6.4 — 6.4 Other 4.7 0.3 5.0 6.0 0.2 6.2 Total revenues $ 749.6 $ 44.8 $ 794.4 $ 641.5 $ 36.2 $ 677.7 (1) Net product sales include both the drug product and the respective inhalation device. (2) Net product sales include sales of infusion devices, including the Remunity Pump. Three Months Ended March 31, Dollar Change Percentage Change 2025 2024 Category: Cost of sales $ 91.6 $ 71.8 $ 19.8 28 % Share-based compensation expense(1) 0.9 1.1 (0.2 ) (18 )% Total cost of sales $ 92.5 $ 72.9 $ 19.6 27 % (1) See Share-based compensation below. Three Months Ended March 31, Dollar Change Percentage Change 2025 2024 Category: External research and development(1) $ 57.2 $ 52.7 $ 4.5 9 % Internal research and development(2) 48.3 44.9 3.4 8 % Share-based compensation expense(3) 6.9 6.4 0.5 8 % Other(4) 36.6 0.1 36.5 NM(5) Total research and development expense $ 149.0 $ 104.1 $ 44.9 43 % (1) External research and development primarily includes fees paid to third parties (such as clinical trial sites, contract research organizations, and contract laboratories) for preclinical and clinical studies and payments to third-party contract manufacturers before FDA approval of the relevant product. (2) Internal research and development primarily includes salary-related expenses for research and development functions, internal costs to manufacture product candidates before FDA approval, and internal facilities-related expenses, including depreciation, related to research and development activities. (3) See Share-based compensation below. (4) Other primarily includes upfront fees and milestone payments to third parties under license agreements related to development-stage products and adjustments to the fair value of our contingent consideration obligations. (5) Calculation is not meaningful. Three Months Ended March 31, Dollar Change Percentage Change 2025 2024 Category: General and administrative $ 119.5 $ 103.1 $ 16.4 16 % Sales and marketing 26.6 23.2 3.4 15 % Share-based compensation expense(1) 24.0 18.1 5.9 33 % Total selling, general, and administrative expense $ 170.1 $ 144.4 $ 25.7 18 % (1) See Share-based compensation below. Three Months Ended March 31, Dollar Change Percentage Change 2025 2024 Category: Stock options $ 8.5 $ 5.7 $ 2.8 49 % Restricted stock units 23.4 15.5 7.9 51 % Share tracking awards plan (0.8 ) 3.9 (4.7 ) (121 )% Employee stock purchase plan 0.7 0.5 0.2 40 % Total share-based compensation expense $ 31.8 $ 25.6 $ 6.2 24 % UNITED THERAPEUTICS CORPORATION CONSOLIDATED STATEMENTS OF OPERATIONS (In millions, except per share data) Three Months Ended March 31, 2025 2024 (Unaudited) Total revenues $ 794.4 $ 677.7 Operating expenses: Cost of sales 92.5 72.9 Research and development 149.0 104.1 Selling, general, and administrative 170.1 144.4 Total operating expenses 411.6 321.4 Operating income 382.8 356.3 Interest income 51.1 53.8 Interest expense (6.1 ) (13.3 ) Other (expense) income, net (4.3 ) 1.8 Total other income, net 40.7 42.3 Income before income taxes 423.5 398.6 Income tax expense (101.3 ) (92.0 ) Net income $ 322.2 $ 306.6 Net income per common share: Basic $ 7.18 $ 6.52 Diluted $ 6.63 $ 6.17 Weighted average number of common shares outstanding: Basic 44.9 47.0 Diluted 48.6 49.7 SELECTED CONSOLIDATED BALANCE SHEET DATA (Unaudited, in millions) March 31, 2025 Cash, cash equivalents, and marketable investments $ 5,032.0 Total assets 7,743.9 Total liabilities 936.7 Total stockholders’ equity 6,807.2 SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)-- United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced its financial results for the quarter ended March 31,... SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C. --(BUSINESS WIRE)-- United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that recent research across its commercial and... SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)-- United Therapeutics Corporation (Nasdaq: UTHR) announced today that it will report its first quarter 2025 financial results before the market opens... SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)-- United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that ten posters and presentations across its... SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)-- United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, announced today that Great Place to Work® and Fortune magazine... SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)-- United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, announced today that James Edgemond, Chief Financial Officer and...

CINCINNATI, April 08, 2025 (GLOBE NEWSWIRE) -- Onconetix, Inc. (Nasdaq: ONCO) (“Onconetix” or the “Company”) (formerly Blue Water Biotech Inc.) and Ocuvex Therapeutics, Inc. (“Ocuvex”), a privately held biopharmaceutical company focused on the development and commercialization of ophthalmic therapeutic candidates to address highly prevalent diseases in need of new treatment options, today announced that they have signed a Non-Binding Letter of Intent contemplating a potential business combination transaction with Ocuvex. Andrew J. Oakley, Chairman of the Board of Onconetix, stated, “We are excited about the opportunity to combine forces with Ocuvex, whose pipeline of commercial and late clinical stage ophthalmic assets will immediately expand our reach beyond oncology , enhancing shareholder value.” Anthony W. Amato, President, CEO of Ocuvex, commented, “With an already FDA approved product, and late stage clinical assets, we believe that combining with Onconetix will allow us to broaden access to capital while continuing to focus on innovation and customer satisfaction. This is an exciting new chapter for our employees, customers, and stakeholders.” Onconetix and Ocuvex will continue negotiations to enter into a definitive agreement. Upon closing of the proposed transaction, Onconetix will acquire all the issued and outstanding equity interests of Ocuvex in exchange for newly issued shares of common stock of Onconetix. Immediately following the closing of the proposed transaction, the pre-closing Ocuvex equity holders will own approximately 90% of the equity interests in Onconetix. The Letter of Intent only represents a mutual indication of interest regarding the proposed transaction, and the terms of any such transaction are subject to a number of contingencies, including the completion of due diligence and the negotiation and execution of a definitive agreement. Completion of the proposed transaction will be subject to customary conditions, including (i) the completion of adequate financing, and (ii) the obtainment of applicable regulatory, stockholder and third-party approvals. There can be no assurance that a definitive agreement will be executed or that the proposed transaction will completed as proposed, or at all. About Onconetix, Inc. Onconetix (Nasdaq: ONCO) is a commercial stage biotechnology company focused on the research, development and commercialization of innovative solutions for men’s health and oncology. Through our recent acquisition of Proteomedix, we own Proclarix®, an in vitro diagnostic test for prostate cancer originally developed by Proteomedix and approved for sale in the European Union (“EU”) under the IVDR, which we anticipate will be marketed in the U.S. as a lab developed test (“LDT”) through our license agreement with Labcorp. We also own ENTADFI, an FDA-approved, once daily pill that combines finasteride and tadalafil for the treatment of benign prostatic hyperplasia (“BPH”), a disorder of the prostate. For more information, visit www.onconetix.com. About Ocuvex Therapeutics, Inc. Ocuvex is a privately funded biopharmaceutical company focused on the development and commercialization of ophthalmic therapeutic candidates to address highly prevalent diseases in need of new treatment options and was formed through the merger of Ocuvex Inc. and Visiox Pharmaceuticals, Inc. in August 2024. Ocuvex’s lead asset, Omlonti® (omidenepag isopropyl ophthalmic solution) 0.002%, is an EP2 receptor agonist for ocular hypertension and open-angle glaucoma. It received FDA approval in September 2022. Forward-Looking Statements Certain statements in this press release are “forward-looking” within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as “anticipate,” “believe,” “forecast,” “estimate,” “expect,” and “intend,” among others. These forward-looking statements (including, without limitation, the anticipated benefits and opportunities that may be generated by the proposed transaction described herein) are based on Onconetix’s current expectations, and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, whether a definitive agreement for the proposed transaction with Ocuvex and any related financing will be entered into; whether such transactions, or any other contemplated transaction, may be completed with different terms, in an untimely manner, or not at all; whether the Company will be able to realize the benefits of the proposed transaction described herein; Onconetix’s ability to integrate the assets and commercial operations contemplated to be acquired from Ocuvex into the Company’s business; market and other conditions; risks related to Onconetix’s ability to commercialize or monetize Proclarix; risks related to the Company’s present need for capital to commercially launch Proclarix and have adequate working capital; risks related to Onconetix’s ability to attract, hire and retain skilled personnel necessary to commercialize and operate the Company’s commercial products; the failure to obtain and maintain the necessary regulatory approvals to market and commercialize Onconetix’s products; risks related to the Company’s ability to obtain and maintain intellectual property protection for its current products; whether the Company will be able to maintain compliance with Nasdaq’s applicable listing criteria and the effect of a delisting from Nasdaq on the market for the Company’s securities; and the Company’s reliance on third parties, including manufacturers and logistics companies. As with any commercial-stage pharmaceutical product or any product candidate under clinical development, there are significant risks in the development, regulatory approval and commercialization of biotechnology products. Onconetix does not undertake an obligation to update or revise any forward-looking statement. Investors should read the risk factors set forth in Onconetix’s Annual Report on Form 10-K, filed with the SEC on April 11, 2024 and periodic reports filed with the SEC on or after the date thereof. All of Onconetix’s forward-looking statements are expressly qualified by all such risk factors and other cautionary statements. The information set forth herein speaks only as of the date thereof, and Onconetix assumes no obligation to update or revise these statements unless otherwise required by law. No Offer or Solicitation This press release does not and shall not constitute an offer to sell or a solicitation of an offer to buy any securities of Onconetix or Ocuvex, nor shall there be any offer, solicitation or sale of such securities, if any, in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. Investor and Media Contact Information: Onconetix, Inc.201 E. Fifth Street, Suite 1900Cincinnati, OH 45202Phone: (513) 620-4101Investor Contact Information: Onconetix Investor RelationsEmail: investors@onconetix.com